Introduction
============

In most patients with early stage breast cancer, adjuvant radiotherapy (RT) is part of a standard of care approach for breast conserving therapy (BCT).[@b1-bctt-7-211] Although BCT was originally validated utilizing whole breast irradiation (WBI) over a 5- to 6.5-week course,[@b2-bctt-7-211] there has since been an international trend aimed at evaluating a reduced number of RT treatments (hypofractionated or accelerated RT) and a reduction in the volume of breast irradiated (partial breast RT). A combination of these two approaches, termed accelerated partial breast irradiation (APBI), is currently being investigated in several large national trials with results pending.[@b3-bctt-7-211] Despite the lack of this mature phase III data, preliminary results suggest that APBI is safe and effective.[@b4-bctt-7-211] As a result, several consensus groups including the National Comprehensive Cancer Network endorse the use of APBI in selecting patients.[@b1-bctt-7-211],[@b4-bctt-7-211]--[@b7-bctt-7-211]

Brachytherapy, an RT technique that places radioactive isotopes within or adjacent to a tumor or tumor bed, has been utilized in cancer care for over a century.[@b8-bctt-7-211] It has the benefit of ultra-high radiation dose delivery to the tissue adjacent to the isotope but a rapid fall-off of radiation dose as distance from the source increases. It is this characteristic of brachytherapy that has made it an ideal choice for APBI: it can be used to treat the lumpectomy cavity to high radiation doses while limiting radiation exposure to the non-involved ipsilateral breast, skin, lung, heart, and contralateral breast. For this reason, the use of brachytherapy to treat breast cancer has gained significant popularity in the last 10--20 years and APBI using brachytherapy devices was included as a technique in the pending international trials of APBI.[@b3-bctt-7-211]

Significant controversy exists in the definition of the "select patients" for whom APBI should be endorsed as a safe and effective option and consensus statements from multiple medical and surgical societies provide conflicting definitions of this group of patients ([Table 1](#t1-bctt-7-211){ref-type="table"}).[@b4-bctt-7-211]--[@b7-bctt-7-211] Moreover, an estimated 60% of patients treated with brachytherapy-based APBI nationally would be considered as "cautionary" or "unsuitable" by consensus expert guidelines.[@b9-bctt-7-211] The purpose of this article is to organize and synthesize the evidence supporting current consensus guidelines for APBI and focus on unique clinical scenarios that could alter breast brachytherapy APBI management. This report is a narrative review of the literature, comprising a search of PubMed and the authors' knowledge of available citations, and does not constitute a formal systematic review or meta-analysis.

Recommending APBI as a part of a BCT approach
=============================================

The rationale for APBI is based on the fact that 90% of ipsilateral breast tumor recurrences (IBTR) occur within 1 cm of the lumpectomy cavity (defined here as local IBTR).[@b10-bctt-7-211] The goal of patient selection for APBI is to define a group of woman that are at risk for local failure and would benefit from adjuvant RT, but are at sufficiently low risk for regional IBTR (defined here as more than 1 cm from the lumpectomy cavity) and sufficiently low risk for nodal and distant failure. It is for these women that APBI is both beneficial and sufficient.

Factors predicting for local IBTR
---------------------------------

Tumor and patient characteristics that serve as predictors of local failure have been identified by the long-term follow-up of several randomized clinical trials.[@b11-bctt-7-211]--[@b14-bctt-7-211] Well-validated factors predictive of increased risk of local failure include: younger age at diagnosis, involved margins, larger size, higher grade, lymph vascular space invasion (LVSI), extensive intraductal component (EIC), estrogen receptor (ER) status, progesterone receptor status, human epidermal growth factor receptor 2, and omission of adjuvant radiation therapy. These factors can be grouped into three groups: patient factors, surgical factors, and tumor biology. Most studies do not distinguish between local IBTR and regional IBTR, mainly because they were comparing BCT with mastectomy, and any IBTR was considered a failure of BCT that mastectomy could have potentially prevented.

Young age is consistently reported to be an independent predictor of IBTR and, in general, younger patients are at higher risk.[@b11-bctt-7-211],[@b13-bctt-7-211]--[@b18-bctt-7-211] One hypothesis is that menopausal status and its interaction with breast cancer hormonal receptors rather than exact age more closely predict recurrence risk. The 15-year follow-up of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 randomized trial showed that both age less than 45 and over 65 years old predicted IBTR.[@b14-bctt-7-211] Wapnir et al evaluated over 2,600 patients enrolled in the NSABP B-17 and B-24 trials and showed a 2.1-fold increased risk of invasive IBTR in patients less than 45 years old compared with those aged 65 years and older.[@b13-bctt-7-211] In regards to APBI, Ott et al evaluated a retrospective series of 274 patients treated with interstitial brachytherapy-based APBI and found that age less than 50 years old was associated with inferior local control.[@b18-bctt-7-211]

Histopathological examination of the lumpectomy specimen provides additional risk factors for IBTR including surgical margin status and tumor diameter. Patients with involved surgical margins were excluded from most prospective randomized trials and there is limited data informing the effect of APBI in the setting of positive margins. Recent expert consensus states that a positive surgical margin is associated with a twofold increase in the rate of IBTR.[@b19-bctt-7-211] Large tumor size (by palpation or pathologic measurement) has a significant effect on local tumor control.[@b15-bctt-7-211] Cefaro et al identified tumor size ≥3 cm was an independent significant factor predicting for local recurrence (a common criteria found among APBI consensus statements).[@b20-bctt-7-211] Interestingly, tumor size has not been associated with IBTR following APBI.[@b17-bctt-7-211] This result should be interpreted with caution because of the selection bias in patients considered eligible for APBI, which is typically limited to patients with tumors smaller than 3 cm.[@b4-bctt-7-211]

As have been well described within the literature, factors indicative of tumor biology that have been independently associated with local recurrence include high grade, the presence of comedonecrosis, LVSI, and EIC.[@b11-bctt-7-211]--[@b17-bctt-7-211],[@b21-bctt-7-211],[@b22-bctt-7-211] Also, there is increasing evidence that hormone receptor status plays a role in recurrence risk. In a pooled analysis of almost 2,000 patients, Shah et al found ER negativity to be the only independent predictor of local failure.[@b23-bctt-7-211]

Factors predicting for regional IBTR: "Elsewhere Failures"
----------------------------------------------------------

Although critical to the success of APBI, there has been variability in the reporting of patterns of failure. Many series report out-of-field IBTRs as a local failure or as a new breast tumor primary. Although either may be true, it is our opinion that series of APBI should evaluate these recurrences as a distinct failure pattern, particularly when brachytherapy is used, in order to understand the pattern of recurrence relative to the conformal brachytherapy dose distribution. Regional IBTR describes tumor recurrence in a location that would be treated to full dose with WBI or excised with total mastectomy but receives negligible dose with APBI. The distinction between a non-contiguous recurrence versus a new ipsilateral primary is of little consequence in evaluating the safety of APBI because any in-breast disease would have been presumably treated with WBI or mastectomy. Recht et al defined this entity as an "elsewhere failure": recurrent disease arising within the ipsilateral breast but at least a few centimeters from the lumpectomy cavity.[@b24-bctt-7-211] Recent pooled series would predict regional IBTR to be on the order of 2% at 5 years for patients eligible for and receiving APBI.[@b23-bctt-7-211]

Considering the variability of reporting within the published series, it is currently difficult to provide factors that would predispose to regional IBTR as opposed to local IBTR. Despite this, there are several factors that are likely to contribute. Multicentric breast cancer is, by definition, regional breast disease that is unlikely to be treated with most APBI techniques except under unique circumstances. Similarly, multifocal breast cancer is likely a risk factor for regional IBTR, conceivably because a negative surgical margin could be reported by bisecting breast tissue separating two distinct islands of tumor cells and therefore leaving disease in the breast. This is reflected in the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus guidelines by permitting microscopic multifocality less than 3 cm total, but not clinically apparent multifocality or islands of tumor spanning more than 3 cm.[@b4-bctt-7-211]

An EIC not only increases the total tumor diameter but has been shown to predict for residual disease after lumpectomy in older mastectomy series.[@b25-bctt-7-211] Modern reports, however, demonstrate that EIC excised to negative margin is not a risk factor for local recurrence after lumpectomy and WBI.[@b26-bctt-7-211] Despite this, when treated with interstitial and balloon brachytherapy-based APBI, local failure was higher in patients with EIC.[@b27-bctt-7-211],[@b28-bctt-7-211] As a result, there are mixed recommendations regarding APBI in patients with EIC and negative surgical margins.

Similar to EIC, APBI for pure ductal carcinoma in situ (DCIS) is somewhat controversial. This is largely based on the fact that the majority of currently available prospective trials of APBI have excluded pure DCIS. However, recent pooled retrospective data show excellent local control after APBI with DCIS.[@b16-bctt-7-211],[@b29-bctt-7-211],[@b30-bctt-7-211]

The multicentric natural history of invasive lobular carcinoma (ILC) led some experts to question the use of APBI in these patients, and there is limited retrospective evidence and no data from randomized trials to evaluate ILC's significance to IBTR, likely because this histology was excluded from many of the historic BCT studies. Additionally, some of the first clinical results of APBI supported this concern.[@b10-bctt-7-211],[@b31-bctt-7-211] Since these study protocols have been developed, however, several modern series clinical data have demonstrated that APBI with brachytherapy is safe in patients with ILC,[@b17-bctt-7-211],[@b18-bctt-7-211],[@b32-bctt-7-211] and consensus groups have revised their criteria to include lobular histology.[@b5-bctt-7-211] Notably, any lobular histology remains "cautionary" under the current ASTRO consensus.[@b4-bctt-7-211]

Although LVSI is a prognostic factor in breast cancer, its significance in APBI patient selection is disputed because of conflicting existing evidence. A single institution reported on 106 patients defined as "cautionary" under ASTRO grouping who underwent APBI.[@b33-bctt-7-211] Among three recurrences, focal LVSI was not predictive of failure. To the contrary, a similar study including 277 patients who received brachytherapy-based APBI reported that LVSI was indeed predictive of local failure.[@b27-bctt-7-211] Although focal LVSI is permitted by ASTRO, any presence of LVSI is considered as "unsuitable" under American Brachytherapy Society (ABS) consensus[@b5-bctt-7-211] mainly based on a lack of existing data.

Factors predicting for nodal or distant failure
-----------------------------------------------

There is little data evaluating risk factors for nodal or distant disease recurrence in patients treated with APBI because most providers would not recommend APBI in patients who are at substantial risk for such a failure. This patient selection bias results in a low incidence of nodal and distant failure and conclusions are difficult to draw, but several important aspects should be highlighted.

The use of APBI in patients with node-positive breast cancer is controversial and in general should not be done outside a clinical trial. Patients with pN1 without extracapsular extension were eligible for enrollment on NSABP B-39 if at least six axillary lymph nodes were examined.[@b3-bctt-7-211] However, there are some small series demonstrating that it may be an appropriate technique in carefully selected patients.[@b34-bctt-7-211] In order to select patients at sufficiently low risk of recurrence outside the breast several factors are considered. Perhaps most important is the surgical evaluation of lymphatic basins. Sentinel lymph-node biopsy (SLNB) generally carries a 7.3% false negative rate but this rate can vary widely (0%--29%).[@b35-bctt-7-211] The significance of a false negative rate of SLNB is mitigated somewhat for patients receiving WBI, due to the fact that standard WBI with opposed tangent photon beams typically includes most of axillary level I lymph nodes. In APBI, however, dose to the axilla is negligible. Under these assumptions, patients receiving APBI are at a real risk for a node-only failure. This reasoning underscores the importance of patient selection and appropriate utilization of adjuvant systemic therapy. During patient selection, factors such as lymph-node biopsy technique as well as primary tumor location, size, and grade should be carefully considered to ensure an adequately high negative predictive value (though a low pretest probability).

Receptor status has become a matter of paramount importance in breast cancer prognosis and treatment. Patients with ER-positive breast cancer have lower rates of nodal and distant failure in general, and this finding has been demonstrated in patients treated with APBI as well.[@b23-bctt-7-211],[@b36-bctt-7-211] Although local control remains excellent, patients with triple negative disease have demonstrated a higher rate and earlier onset of nodal and distant recurrence.[@b37-bctt-7-211] Consequently, most consensus guidelines include receptor status in APBI eligibility criteria.

Consensus group recommendations
-------------------------------

Several cooperative groups including ASTRO, the ABS, American Society of Breast Surgeons (ASBS), and the Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology (GEC-ESTRO) have published consensus guidelines on the appropriate selection of patients for APBI.[@b3-bctt-7-211]--[@b6-bctt-7-211] These recommendations are based on clinical evidence from randomized trials, prospective studies, and expert opinion. The selection criteria recommended by each of these groups (ASTRO, ABS, ASBS, and GEC-ESTRO) are outlined in [Table 1](#t1-bctt-7-211){ref-type="table"}. Additionally, provided are the inclusion criteria for the current ongoing clinical trial, NSABP B-39, which is evaluating the use of APBI in comparison with standard WBI.[@b3-bctt-7-211]

As demonstrated, the consensus group recommendations align regarding many APBI criteria including size (\<3 cm) and margin status (negative or \<2 mm). However, there is some variability in the recommendations regarding histology, the presence of DCIS, EIC, and multifocal tumors. It is well documented that older age is linked to higher local control and all current guidelines agree that patients ≥50 years old should not be excluded from APBI based on age alone. NSABP B-39 has included all patients ≥18 years old, which may provide further clarification regarding which patients should be eligible for APBI.

As discussed earlier, there is limited evidence regarding APBI in patients with ILC, and consensus recommendations are mixed. While it is excluded from the "suitable" and "low-risk" groups of the ASTRO and GEC-ESTRO consensus guidelines, it is not included in the final consideration of the other consensus statements.

EIC was associated with a higher risk of IBTR in the MammoSite registry data, thus patients with EIC ≤3 cm are considered as ASTRO "cautionary" and those with EIC \>3 cm are "unsuitable". Similarly, pure DCIS ≤3 cm is considered as "cautionary" while more extensive DCIS is "unsuitable".

Regarding multifocal disease, the GEC-ESTRO guideline excludes multifocal tumors from the low-risk group, given the lack of published data on outcomes with these patients. ASBS and ABS do not comment on multifocality and the NSABP B-39 inclusion criteria has followed ASTRO allowing microscopic multifocality \<3 cm total.

Candidates for APBI should undergo axillary staging with either SLNB or axillary node dissection. Data from the early APBI trials that did not have complete pathologic axillary staging suggest higher rates of recurrence in those patients treated with APBI.[@b31-bctt-7-211] All consensus guidelines (except for the GEC-ESTRO "intermediate-risk" group) advise against the use of APBI in node-positive patients. Patients should have documented node negative or only isolated foci (\<0.2 mm) of microscopic tumor cells to be considered as "suitable", as per ASTRO recommendations. A recent and useful nomogram developed by Wobb et al provides a method for predicting locoregional failure based on several of the factors discussed here.[@b36-bctt-7-211]

### Potential criticisms of consensus guidelines

Analysis of patients treated with APBI in recent years has identified some limitations in the current consensus statement guidelines. To date, only a single study has shown a statistically significant difference in IBTR between ASTRO consensus statement groups following APBI.[@b38-bctt-7-211] Other studies have demonstrated that the current ASTRO consensus guidelines are not predictive of IBTR in patients treated with APBI,[@b39-bctt-7-211],[@b40-bctt-7-211] and that "cautionary" group patients have acceptably low rates of IBTR.[@b33-bctt-7-211],[@b41-bctt-7-211]--[@b43-bctt-7-211] Although the follow-up duration of many of these series remains less than 10 years, they will undoubtedly contribute to refinement of the consensus guidelines as they continue to mature.

A recent pooled analysis of a large cohort of patients treated at William Beaumont Hospital and the ASBS MammoSite Registry reports no significant difference in the rate of IBTR or true recurrence/marginal miss based on ASTRO consensus statement groups.[@b39-bctt-7-211] Patients in the "cautionary" and "unsuitable" categories did have trend toward higher rates of regional IBTR and new primaries. The authors of this large cohort analysis propose that the current ASTRO guidelines fail to adequately differentiate patients at increased risk of regional IBTR from local IBTR, likely due to the limited available clinical data on APBI.

As aforementioned, data on the outcomes of pure DCIS treated with APBI are limited. Pure DCIS is currently considered as "cautionary" on the ASTRO consensus guidelines and "intermediate risk" on the GEC-ESTRO guidelines. There is some evidence supporting APBI in patients with pure DCIS. A study of over 1,600 women treated with APBI has shown no association between DCIS and risk of local recurrence.[@b17-bctt-7-211] Additionally, a recent analysis by Vicini et al reports excellent outcomes of 300 women with DCIS treated with APBI with no significant difference in the rate of IBTR between the cautionary DCIS group compared with both a pooled suitable/cautionary invasive group and invasive "suitable" risk patients.[@b29-bctt-7-211] These data along with several other series with similar results suggest that patients with pure DCIS less than 3 cm total could be included in the "suitable" category and safely treated with APBI.[@b16-bctt-7-211],[@b33-bctt-7-211],[@b41-bctt-7-211]

While there is likely overlap between the factors predicting local IBRT and those predicting regional IBTR, some patients may fail regardless of treatment modality and may have been eligible for the BCT with WBI. McHaffie et al demonstrated that women with DCIS or age 50--59 as their only "cautionary" risk factor that otherwise would have met "suitable" criteria had excellent locoregional control compared with other "cautionary" patient factors.[@b41-bctt-7-211] Several other recent analyses of patients treated with APBI have shown that ER-negative tumors have a higher local recurrence compared with ER-positive patients.[@b33-bctt-7-211],[@b43-bctt-7-211] Beitsch et al identified ER-negative status as the only predictor of 5-year IBTR following APBI.[@b42-bctt-7-211] Together, the presented studies provide evidence for revisions in the current consensus statements that are likely to occur as data mature.

Brachytherapy-specific considerations
=====================================

High dose rate versus low dose rate
-----------------------------------

Low dose-rate (LDR) brachytherapy isotopes have been the gold standard for brachytherapy sources for decades, including in breast APBI.[@b44-bctt-7-211],[@b45-bctt-7-211] In recent years, however, there has been a global increase in the utilization of high dose-rate (HDR) sources. The reasons for this are multifactorial but include improved patient and staff safety, convenience, and potentially a radiobiological advantage. HDR first demonstrated effectiveness compared with LDR when delivered as a local boost after WBI.[@b46-bctt-7-211],[@b47-bctt-7-211] There were concerns, however, that an increase in dose rate could have radiobiological effects that could result in inferior cosmesis or possibly tumor control.

The Radiation Therapy Oncology Group (RTOG) compared LDR sources with HDR sources for APBI in a phase II trial accruing in the late 1990s (RTOG 9517). LDR prescription was 45 Gy over 3.5--5 days and HDR was 34 Gy in 10 fractions twice-daily over 5 days. Early results demonstrated less grade 3--4 toxicity within the HDR arm,[@b48-bctt-7-211] and with 6-year follow-up there were similar rates and patterns of failure between arms.[@b49-bctt-7-211] Considering the advantages in safety and convenience with HDR brachytherapy, HDR sources like Iridium-192 have replaced LDR for the treatment of breast cancers in many radiation therapy centers in the United States.

The Xoft Axxent electronic brachytherapy device (Xoft, Inc., Sunnyvale, CA, USA) is a more recent development in brachytherapy that has demonstrated usefulness in APBI since its Food and Drug Administration (FDA) approval in 2006.[@b50-bctt-7-211]--[@b52-bctt-7-211] This device utilizes electricity to create a low energy (50 kV) source similar to that of other APBI techniques.[@b53-bctt-7-211],[@b54-bctt-7-211] An obvious benefit of the Xoft system is that it is not radioactive, which could further improve patient and staff safety. Additionally, these low energy sources do not require the intensive shielding needed for iridium sources and therefore can be used in unshielded operating rooms. The drawbacks to this low energy source include the limiting surface dose (at the surface of the applicator), a problem that can be overcome with HDR sources, which can have a more homogeneous dose distribution.[@b54-bctt-7-211],[@b55-bctt-7-211]

Applicator selection
--------------------

There are numerous applicators available for use in breast brachytherapy and applicator selection should depend on patient-specific anatomy and surgical findings, but selection is commonly limited by applicator availability and user expertise. The first breast brachytherapy applicators reported were breast bridges, in which interstitial needles were placed through a template into the breast.[@b46-bctt-7-211],[@b47-bctt-7-211],[@b49-bctt-7-211] This technique has the advantage of being highly customizable although user technique is critical and treatment planning is time intensive. The Harrison--Anderson--Mick silastic applicator (Mick Radio-Nuclear instruments, Mount Vernon, NY, USA) can be thought of as several needles fixed within a rectangular silicone mold. Although the Harrison--Anderson--Mick applicator has demonstrated clinical effectiveness,[@b56-bctt-7-211],[@b57-bctt-7-211] depending on the shape of the lumpectomy cavity it can be bulky. Revisions to this design have been made but they remain in early stages of development.[@b56-bctt-7-211]

The most popular applicator devices in the US are balloon-based. These applicators are placed directly into the lumpectomy cavity and inflated with water or saline (with a small amount of contrast material added). This process provides a customized treatment plan for each patient and improves dose homogeneity. Original balloon-based applicators like the MammoSite single-lumen (Hologic, Marlborough, MA, USA) contained a single channel for the HDR source. Although dose could be optimized longitudinally (along the path of the source), radial dose was always uniform (perpendicular to the path of the source). The addition of multiple catheters through the balloon has allowed for radial dose variation and optimization, and has made balloon-based brachytherapy more customizable.[@b55-bctt-7-211],[@b58-bctt-7-211],[@b59-bctt-7-211]

Several additional lumpectomy HDR applicators that serve as a hybrid of those listed previously are available and early clinical results are favorable. These include the strut adjusted volume implant[@b60-bctt-7-211]--[@b63-bctt-7-211] (Cianna Medical, Aliso, Viejo, CA, USA) and the ClearPath[@b64-bctt-7-211] (North American Scientific, Chatsworth, CA, USA). A comprehensive review summarizing the pros and cons of various APBI applicators is outside the scope of this review but available within the existing literature.[@b65-bctt-7-211]

Noninvasive image-guided breast brachytherapy
---------------------------------------------

Brachytherapy has historically referred to the placement of radioactive isotopes into or adjacent to the tumor bed, but the distinction between this "traditional" brachytherapy and external beam RT has become increasingly blurred with advancements in technology. An example illustrating this point is noninvasive image-guided breast brachytherapy (NIBB). To the authors' knowledge, AccuBoost (Advanced Radiation Therapy, Inc., Billerica, MA, USA) is the only FDA-approved device for NIBB to date. This device involves breast immobilization with compression and kV orthogonal imaging. After planning and optimization, an HDR after-loader delivers the prescription dose from opposed orthogonal beams to the tumor bed (four total beams). Although most widely used as a tumor bed boost given prior to WBI,[@b66-bctt-7-211]--[@b68-bctt-7-211] early results suggest that NIBB can be used safely for APBI.[@b69-bctt-7-211] Mature data demonstrating the efficacy for NIBB for APBI, and compared with other APBI techniques, are pending.

Image-guided brachytherapy
--------------------------

Although early breast brachytherapy (specifically intraoperative RT \[IORT\]) was delivered without image guidance, the use of imaging modalities used to confirm the proper placement of the applicator and improve dose optimization has become a critical component of brachytherapy. Image guidance can also serve to abort applicator placement in patients thought to not be safe for breast brachytherapy, such as having too high of a projected skin dose or too large of a lumpectomy cavity. One study reported that this frequency could be as high as 19% of patients planned for IORT.[@b70-bctt-7-211]

The images collected with the applicator *in situ* can provide a means of optimizing the dose delivered and sparing adjacent normal structures. First reported for APBI in 1997, ultrasound has now become the most ubiquitous modality used for postoperative applicator placement.[@b71-bctt-7-211]--[@b73-bctt-7-211] Benefits to ultrasound include that it is easy to use, inexpensive, and non-ionizing. If the applicator is placed in the operating room, then ultrasound can also be used to confirm applicator positioning and the lack of air within the lumpectomy cavity.[@b53-bctt-7-211]

The sensitivity of mammography in detecting breast abnormalities makes it ideal for use as image guidance in brachytherapy. Although portal and kV imaging has been used in breast brachytherapy since its inception, high-quality mammography has been used minimally for guidance until recent years. The AccuBoost system utilizes its on-board kV imaging system to collect orthogonal compression mammograms for lumpectomy cavity localization and planning. Although early toxicity results are favorable, clinical outcomes are currently pending.[@b66-bctt-7-211]--[@b69-bctt-7-211]

Computed tomography (CT) scanners are common within RT centers and RT staff is well accustomed to the CT-plan-treat workflow. In the case of needle-based brachytherapy applicators, CT guidance may provide benefit in needle placement and resultant dosimetry.[@b74-bctt-7-211]--[@b76-bctt-7-211] For balloon-based applicators, CT imaging can also provide aid in terms of placement and improved computer-based planning and optimization.[@b55-bctt-7-211],[@b77-bctt-7-211]

Although the role of magnetic resonance (MR) imaging in breast brachytherapy remains to be defined, there are several potentially interesting applications. Jolicoeur et al reported on 70 patients who underwent CT-and MR-based simulation and APBI planning at their institution.[@b78-bctt-7-211] Their results suggest that MR-based planning results in a smaller and more accurately defined target volume than CT-based planning. They comment that MR-based simulation could obviate the need for surgical clip placement at the time of lumpectomy. The use of CT+MR imaging in breast brachytherapy will provide for interesting analyses in the future.

Intraoperative brachytherapy
----------------------------

IORT is a form of APBI that has been reported in two large European trials with favorable outcomes using kV photon[@b79-bctt-7-211] and MV electron[@b80-bctt-7-211] techniques. Although a full comparative discussion is outside the scope of this review, there are several logistic and dosimetric concerns to external beam-based IORT, and breast brachytherapy is poised to overcome several of these drawbacks.[@b81-bctt-7-211]

Although still in an investigational phase, balloon-based HDR breast IORT can be utilized to give a focused, homogeneous dose to a small volume of breast tissue.[@b55-bctt-7-211] At our institution, we have an active protocol accruing patients to receive an IORT single 12.5 Gy dose prescribed to 1 cm from the balloon surface, which provides a dose chosen to deliver a similar surface dose as the kV photon IORT trial. A balloon-based multichannel catheter is placed immediately following lumpectomy and a planning CT scan is performed using in-room CT imaging. RT is delivered using an HDR source (Iridium-192) to 1 cm from the surface of the balloon.[@b55-bctt-7-211] Although the procedure is performed in a dedicated brachytherapy suite with full anesthesia capabilities, HDR shielding, and a CT-on-rails system,[@b82-bctt-7-211] we believe that the results will provide meaningful insight into breast IORT that can be expanded to centers with more standard HDR delivery systems.

Dose and fractionation
----------------------

Akin to the debate over the optimal external beam dose and fractionation, considerable debate exists over the optimal dose and fractionation of HDR breast brachytherapy that optimizes tumor control and minimizes toxicity. The optimal dose and fractionation for use in APBI with brachytherapy is a subject for debate. Breast brachytherapy was first validated with LDR doses of 50 Gy given over 4--5 days following inpatient admission.[@b44-bctt-7-211],[@b83-bctt-7-211] Since then, LDR doses have ranged from 20 to 60 Gy in select series.[@b3-bctt-7-211],[@b84-bctt-7-211] As discussed earlier, however, LDR utilization is being replaced at many centers with HDR sources.

The earliest and largest series of APBI with HDR brachytherapy deliver 34--38 Gy twice-daily separated by 6 hours over 5 days (10 total fractions).[@b3-bctt-7-211],[@b49-bctt-7-211],[@b85-bctt-7-211],[@b86-bctt-7-211] However, the "typical dose" of 34 Gy over 10 fractions is hardly the only dose validated and a wide range of HDR doses have been reported from 20 Gy in 2 fractions to 37.2 Gy in 10 fractions.[@b3-bctt-7-211],[@b85-bctt-7-211]

The utilization of IORT will provide an interesting extension into the breast cancer alpha/beta ratio and, consequently, brachytherapy dosing and fractionation. If single fraction IORT provides equivalent long-term local control and toxicity outcomes, there will likely be a movement toward single fraction postoperative APBI using breast brachytherapy. A caution, of course, is that many forms of breast IORT utilize unique delivery mechanisms (eg, kV photons) that are not directly biologically comparable to HDR balloon-based brachytherapy. To date, there have been no randomized trials directly comparing HDR doses used in breast brachytherapy and the majority of reported data (as well as the current national cooperative group trial)[@b3-bctt-7-211] recommend 34 Gy in 10 fractions twice-daily as the standard APBI dose.[@b3-bctt-7-211],[@b28-bctt-7-211]

Post-augmentation or reconstruction
-----------------------------------

APBI is particularly difficult when cancer is detected in a breast following augmentation, when the placement of the capsule can distort normal breast anatomy and risk contracture following RT. Brachytherapy in an augmented breast has been described for over 20 years,[@b87-bctt-7-211],[@b88-bctt-7-211] however, only case reports have been published using strut-adjusted volume implants[@b89-bctt-7-211] or multilumen balloon applicators in the augmented breast.[@b90-bctt-7-211] These case reports each demonstrate favorable dosimetric and cosmetic results, although larger series are yet unpublished.

Distortion of the tumor bed at the time of lumpectomy through autologous tissue transfer (ie, oncoplastic reconstruction) results in difficulty defining the target volume for APBI. Recently, Roth et al retrospectively analyzed 134 patients who received oncoplastic surgery followed by interstitial needle-based ABPI.[@b91-bctt-7-211] They utilized pathologic evaluation, physical exam, and all available imaging to define a customized target volume for each patient. Their results suggest that breast brachytherapy is safe following oncoplastic surgery as there were few recurrences, but the median follow-up duration was 39 months and more mature data are pending.

Implanted cardiac devices
-------------------------

Photon interactions with implanted cardiac devices (ie, pacemakers and defibrillators) can result in a life-threatening malfunction depending on the patient's cardiac disease and device status. Increasing the distance between the radioactive source and the device provides the most reduction in dose delivered to it. Unfortunately, unless the cardiac device is relocated to the other side of the chest, the distance between the lumpectomy cavity and the device is relatively fixed. Depending on patient anatomy, breast brachytherapy would likely offer a reduction in dose delivered to the device compared with standard WBI and external beam APBI. Although limited and highly patient specific, there are several small series of balloon-based breast brachytherapy in patients with cardiac devices demonstrating favorable dosimetric and clinical outcomes.[@b92-bctt-7-211]--[@b94-bctt-7-211]

Brachytherapy for local recurrence
----------------------------------

Given the favorable survival outcomes demonstrated in women with early stage breast cancer treated with BCT, an increasing number of women may present with breast cancer in an intact, previously irradiated breast. Historically, mastectomy had been the standard of care for these IBTR (or ipsilateral new primary) tumors. Currently, the RTOG 1,014 trial is evaluating the use of repeat breast conservation and 3-D conformal re-irradiation in women previously treated with lumpectomy and whole breast radiation.[@b95-bctt-7-211] There are currently no randomized controlled trials to evaluate the use of breast conservation with brachytherapy for locally recurrent disease; however, various single-institution studies have reported their experience.

There are at least three separate single-institution reports of brachytherapy after second lumpectomy for recurrent breast cancer after WBI. Together, the mastectomy-free survival ranges from 73% to 94.4% with limited follow-up to date.[@b96-bctt-7-211]--[@b98-bctt-7-211] In a phase II study by Chadha et al, 15 patients with a localized IBTR underwent a second lumpectomy and LDR brachytherapy to 30 or 45 Gy.[@b96-bctt-7-211] They reported excellent overall survival and local control (ie, mastectomy free survival) rates of 100% and 89%, respectively, with a median of 36 months follow-up. The single patient with a local recurrence at 27 months received 30 Gy. Further, there was no grade 3 or 4 toxicity reported. These data suggest that patients previously treated with breast conservation may be candidates for re-irradiation with acceptable toxicity and outcomes, although further prospective data are warranted.

Conclusion
==========

APBI is aimed to prevent failure within the lumpectomy cavity but not necessarily elsewhere. As such, selecting patients at high enough risk for local failure to warrant adjuvant therapy but a low enough risk for out of field failures (regional IBTR, regional nodal recurrence, and distant metastasis) is a key to select patients who will benefit from APBI. Brachytherapy can provide focused, high-dose RT to the area at highest risk for local failure and is an excellent option. APBI needs to be customized to each patient based on anatomy, patient comorbidities, and tumor-specific characteristics and these are the each hallmark of brachytherapy. APBI brachytherapy can be considered in select cases and these patients should be referred to specialized centers with sufficient expertise. Results of several large international trials are pending, which will guide further recommendations regarding APBI and breast brachytherapy. Until then several guidelines exist for patient selection, and a careful examination of the rationale behind these recommendations provides meaningful insight into the disease biology.
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###### 

Criteria for accelerated partial breast irradiation appropriateness by consensus statement or clinical trial

                                         ASBS[@b6-bctt-7-211]           ASTRO "suitable"[@b4-bctt-7-211]   ASTRO "cautionary"[@b4-bctt-7-211]   GEC-ESTRO low-risk group[@b7-bctt-7-211]   GEC-ESTRO intermediate-risk group[@b7-bctt-7-211]   NSABP B-39[@b3-bctt-7-211] (in progress)                   ABS[@b5-bctt-7-211]
  -------------------------------------- ------------------------------ ---------------------------------- ------------------------------------ ------------------------------------------ --------------------------------------------------- ---------------------------------------------------------- ---------------------
  Published                              2008                           2009                               2009                                 2010                                       2010                                                2011                                                       2013
  **Risk of local IBTR**                                                                                                                                                                                                                                                                                  
  Tumor size                             ≤3 cm                          ≤2 cm                              2.1--3.0 cm                          ≤3 cm                                      ≤3 cm                                               ≤3 cm                                                      ≤3 cm
  Margin                                 Negative                       ≥2 mm                              Close (\<2 mm)                       ≥2 mm                                      Close (\<2 mm)                                      Negative                                                   Negative
  Hormonal status                        --                             Positive                           Negative                             Any                                        Any                                                 Any                                                        Any
  **Risk of regional IBTR**                                                                                                                                                                                                                                                                               
  Histology                              Any                            Ductal                             Lobular                              Ductal                                     Any                                                 Any                                                        Any
  LVSI                                   --                             None                               Limited                              None                                       None                                                Yes                                                        None
  Pure DCIS                              Yes                            No                                 Yes                                  No                                         Yes                                                 Yes                                                        Yes
  Multifocal                             --                             Clinically unifocal, ≤2 cm total   Clinically unifocal, ≤3 cm total     Unifocal                                   Yes, within \<2 cm of index lesion                  Microscopic, \<3 cm total                                  --
  Multicentric                           --                             Unicentric                         Unicentric                           Unicentric                                 Unicentric                                          Unicentric                                                 --
  **Risk of nodal or distant failure**                                                                                                                                                                                                                                                                    
  Age (years)                            ≥45 if invasive, ≥50 if DCIS   ≥60                                50--59                               ≥50                                        \>40--50                                            ≥18                                                        ≥50
  Nodal status                           pN0                            pN0                                pN0                                  pN0                                        pN1mi, pN1a (by ALND)                               pN0--1[\*](#tfn1-bctt-7-211){ref-type="table-fn"} no ECE   pN0

**Note:**

At least six axillary nodes pathologically evaluated if pN1.

**Abbreviations:** ABS, American Brachytherapy; ALND, axillary lymph node dissection; ASBS, American Society of Breast Surgeons; ASTRO, American Society for Therapeutic Radiology and Oncology; DCIS, ductal carcinoma in situ; ECE, extracapsular extension; GEC-ESTRO, Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology; IBTR, ipsilateral breast tumor recurrence; LVSI, lymphovascular space invasion; NSABP, National Surgical Adjuvant Breast and Bowel Project; pN, pathologic nodal status; --, not included in the criteria.
